Insider at

04

Insider transactions

05
0 buys (P) 0 sells (S) Net: $0 + 8 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

No open-market trades on record; showing all filings.

DateTickerCodeSharesPriceValue Owned afterΔ ownA/Dvs now
April 29, 2026 EBS A 100,111 · · 177,914 Direct +128.67% Acquired (price as of 2026-10-02)
March 5, 2026 EBS F 10,636 $8.44 $89,768 77,803 Direct -12.03% Disposed -25.0% (price as of 2026-10-02)
March 3, 2026 EBS A 44,834 · · 147,833 Direct +43.53% Acquired (price as of 2026-10-02)
Dec. 14, 2025 EBS F 3,543 $11.41 $40,426 88,439 Direct -3.85% Disposed -44.5% (price as of 2026-10-02)
March 6, 2025 EBS A 62,500 · · 91,982 Direct +211.99% Acquired (price as of 2026-10-02)
March 6, 2025 EBS A 62,500 · · 102,999 Direct +154.32% Acquired (price as of 2026-10-02)
Dec. 15, 2024 EBS A 29,482 · · 29,482 Direct · Acquired (price as of 2026-10-02)
Dec. 15, 2024 EBS A 40,499 · · 40,499 Direct · Acquired (price as of 2026-10-02)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.

06
DateTickerSecurityUnderlying Exercise priceExpirationSharesA/D
March 3, 2026 EBS Employee Stock Option (Right to buy) Common Stock (44,834) $8.99 March 2, 2033 44,834 Acquired
March 6, 2025 EBS Employee Stock Options (Right to Buy) Common Stock (62,500) $5.80 March 5, 2032 62,500 Acquired
Dec. 15, 2024 EBS Employee Stock Option (Right to buy) Common Stock (40,499) $8.48 Dec. 14, 2031 40,499 Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Initial ownership (Form 3) 1 holding

07

Securities held when first becoming an insider, per SEC Form 3.

DateTickerSecuritySharesOwnership
Nov. 21, 2024 EBS Common Stock 0 Direct

Compensation (DEF 14A)

08

Matched by name from proxy statements (DEF 14A) — verify against the filing.

EBS

Chief Medical Officer and Head of Research and Development
Fiscal yearSalaryBonusStock awards Option awardsNon-equity incentivePension changeOtherTotal
2025 $545,002 · · · $289,668 · $10,500 $1,471,276

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.